This is important. There has been a lot of contradictory data on whether long term maintenance increases overall survival (OS) enough to justify the side effects and cost. This retrospective study, done on multiple myeloma patients in Europe, seems to support it.
An important prognostic development was announced earlier this year by researchers in England. Check out this excerpt from MedPageToday’s special report, Mutations in Myeloma Predict Outcome:
More and more companies are picking up the bill for dozens of new clinical trials. As the number of trials grow, I’m hopeful that some will ease up and broaden their criteria, allowing nonsectretors like me to participate.
Don’t sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda’s oral proteasome inhibitor (MLN9708) at this year’s ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015.
While our brand new CrowdCare Foundation continues to raise money to help support two specific T cell therapies, the MMRF embraces a much broader mission. I’m pleased to announce that the MMRF has now tested 1000 newly diagnosed patients that have agreed to be monitored from beginning to end. Tracking their progress–through a variety of […]
This is complicated stuff. Apparently Amgen, (now own Onyx who makes Kyprolis) is partnering up with others to try and move into the immunotherapy and T cell therapy space. I’m not sure I understand why they need a partner to do this, but money is BIG!
Amgen, Xencor to Partner on Cancer Immunotherapy, Inflammation Drugs
September 16 […]
Say it ain’t so! Don’t get diagnosed with multiple myeloma in England, Northern Ireland, Scotland or Wales. New austerity measures could result in an early death sentence for our brothers and sisters with myeloma in the UK. I wasn’t planning to write about this today, but I became so upset after reading an article on […]
As you’ve probably guessed by now, Dr. Tricot is a man of few words. Not known to use superlatives, a comment like, “I’m pleased with your results,” jumps out at you. But before everyone gets too excited, I need to add an asterisk. Turns out things are complicated.
The myeloma world doesn’t stop spinning just because I’m waiting for test results. With so much excitement surrounding the immunotherapies elotuzumab and daratumumab, another promising new drug, ixazomib (MLN9708), is often overlooked.
I’ve been openly excited about the prospects of various T cell therapies recently. Early T cell therapy may not be a cure, but it has the potential to be in time. Here’s a rundown of positive early results I found online Thursday, published in the Nature Medicine Journal and reviewed by Womens Fitness:
T-cell receptor therapy […]
Our dear friend, David from Tampa, had a busy summer. A family vacation, catching up work at his consulting business and all things medical are all great signs that he continues to recover successfully. I’ll get you links to the family stuff on CaringBridge at the end of the post. As you would expect, let’s […]
I just heard from a patient’s daughter. Her mother is joining a clinical trial for ABT-199 at Mayo Clinic in Minnesota. Apparently the myeloma team there is openly enthusiastic about the drug’s potential.
Important news as the promising new immunotherapy, daratumumab, continues to move swiftly toward FDA approval.
Efra, a reader from Israel, forwarded me an interesting article about cancer research–done at Mayo Clinic here in Jacksonvile. I got such a kick out of that. Love it or hate it, the internet helps keep us connected. What a small world!
I’m part of an important broadcast Monday evening. Myeloma specialist, Dr. Ola Landgren, has been too busy to do interviews since moving his practice to Memorial Sloan-Kettering Cancer Center in New York. He’s making an exception of us. The topic: Can focusing on high risk myeloma help us find a cure? Remember, anyone who’s relapsed […]
After hearing from dozens of you about your peripheral neuropathy–and what you do to help minimize the symptoms–I’m working on a two part series about it, sharing tips from more than 20 patients; I’ll run the posts this weekend. In the meantime, here is CrowdCare Foundation’s official press release, announcing our support for two important, […]
A reader reminded me today, “Myeloma is not for wimps!” So true, Terri! Now at day 40, following my modified auto stem cell transplant, I continue to get stronger every day. But a new concern is threatening my recovery.
I just listened to one of the best and easiest to understand videos I’ve found, explaining how the new monoclonal antibodies (elotuzumab and daratumumab) work.
Today is your last chance to participate in a focus group study using your smart phones. Amazon gift cards will be given to all who participate.
I think most myeloma experts would agree: its time for a myeloma staging system that incorporates genetic risk assessment. Italian specialist, Dr. Palumbo, and his team are proposing docs worldwide use their new system.